View details of this raise on Seedstage

Boston, MA

Developing a ghrelin-based therapy for persistent concussion symptoms.

• Innovative Therapy: OXE103 is a first-in-class ghrelin therapy targeting persistent concussion symptoms.
• Clinical Success: Phase 2a trial showed an 85% responder rate in patients with persistent concussion symptoms.
• Strategic Partnerships: Backed by $100+ million in development data from Daiichi Sankyo.
• Experienced Leadership: Led by a team with prior companies achieving $9 billion in exits.
• Upcoming Phase 2b Trial: Phase 2b trial planned to enroll 160 patients, aiming to validate FDA-accepted endpoints.

Oxeia Biopharma is developing OXE103, a ghrelin-based therapy aimed at treating persistent concussion symptoms, a condition affecting millions of Americans annually with no FDA-approved treatments available. The company has demonstrated an 85% responder rate in a Phase 2a trial conducted at the University of Kansas Medical Center. This investigational therapy is supported by significant development data from Daiichi Sankyo and is backed by notable figures such as NFL quarterback Alex Smith and cornerback Richard Sherman.

The company is advancing towards a Phase 2b trial, which is a critical step in the regulatory pathway for potential FDA approval. The trial will enroll 160 patients and aims to validate the first FDA-accepted endpoints for concussion therapeutics. Oxeia Biopharma’s leadership team brings extensive experience in clinical development and strategic exits, with prior companies achieving significant acquisitions. The funding will support the Phase 2b trial, positioning OXE103 for potential strategic partnerships and further development.

Company Info

Oxeia Biopharma is developing OXE103, a ghrelin-based therapy for treating persistent concussion symptoms.

Oxeia Biopharma is focused on developing OXE103, a novel ghrelin-based therapy aimed at treating persistent concussion symptoms. The company addresses a significant unmet need, as millions of Americans suffer from concussions annually with no FDA-approved treatments available. OXE103 has shown promising results in a Phase 2a trial, with an 85% responder rate, indicating potential efficacy in alleviating symptoms such as headaches, cognitive impairment, and emotional dysregulation.

The company leverages extensive development data from Daiichi Sankyo, which has accelerated its clinical timeline. Oxeia’s leadership team brings substantial experience in drug development and regulatory pathways, positioning the company to advance OXE103 through further clinical trials. The planned Phase 2b trial will evaluate the therapy’s efficacy in a larger patient population, aiming to establish a new treatment category for concussion therapeutics.